PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
ProPhase Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
31.9%+0.1 pts over 5 years
Operating margin
-415.4%−401.0 pts over 5 years
Net margin
-339.3%−324.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -35.8% | -67.2% | -21.4% | +5.6% | |
| Gross profit | – | -73.0% | -21.4% | +5.2% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -38.8% | -19.5% | -271.5% | |
| Return on assets | -20.8% | -9.7% | -24.0% | |
| Current ratio | 1.41 | 2.52 | 0.06 | |
| Debt to equity | – | – | – | |
| Net debt to EBITDA | – | – | – | |
| Interest coverage | -12.5× | -7.1× | -2.6× | |
| Inventory turnover | 0.9× | 4.4× | 4.9× | |
| Capex to revenue | 15.5% | 11.6% | 0.0% | |
| Diluted shares | 2M | 1M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
ProPhase Labs generated $79.94M from operations and spent $28.70M on capital expenditure, dividends and share buybacks. 39% of that went back into the business.
Generated
$79.94M
Used
$28.70M
Capital expenditure$11.14M39%Dividends$13.90M48%Share buybacks$3.66M13%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-339.3%
×Asset turnover0.07×
×Equity multiplier11.33×
=Return on equity, FY2025-271.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -339.3% | 0.07× | 11.33× | -271.5% |
| FY2024 | -788.2% | 0.09× | 2.73× | -188.1% |
| FY2023 | -48.0% | 0.39× | 1.59× | -29.7% |
| FY2022 | 15.1% | 1.39× | 1.45× | 30.2% |
| FY2021 | 7.9% | 1.31× | 1.74× | 18.1% |
| FY2020 | -14.6% | 0.66× | 2.00× | -19.5% |
| FY2019 | -31.9% | 0.60× | 1.19× | -22.7% |
| FY2018 | -13.3% | 0.48× | 1.13× | -7.2% |
| FY2017 | 411.4% | 0.42× | 1.23× | 214.7% |
| FY2016 | -68.2% | 0.30× | 1.87× | -38.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$14.74M
- Cash generatingOperating cash flow above zero-$8.34M
- Return on assets improvedROA up on the prior year-58.1% → -23.3%
- Earnings backed by cashOperating cash flow above net income-$8.34M vs -$14.74M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose0.95 → 0.06
- No dilutionShare count did not rise2M → 8M
- Gross margin improvedGross margin up on the prior year-2.22% → 31.85%
- More efficientAsset turnover rose0.07 → 0.07